Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUPLINEURO is a multi-ingredient neuro-supportive formulation developed by Neurogenics Therapeutics, primarily used for the management of peripheral and diabetic neuropathies. It combines Methylcobalamin, Alpha Lipoic Acid, Pyridoxine, and Folic Acid to address nerve damage and nutritional deficiencies. Methylcobalamin, a bioactive form of Vitamin B12, facilitates the synthesis of the myelin sheath and promotes axonal regeneration. Alpha Lipoic Acid serves as a potent antioxidant that neutralizes reactive oxygen species, thereby reducing oxidative stress-induced nerve injury and improving endoneurial blood flow. Pyridoxine and Folic Acid support essential metabolic pathways, including homocysteine regulation and neurotransmitter synthesis, which are critical for maintaining optimal neurological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SUPLINEURO.